SAN
DIEGO, Nov. 2, 2023 /PRNewswire/ -- Poseida
Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene
therapy company advancing a new class of treatments for patients
with cancer and rare diseases, today announced the acceptance of
three poster presentations at the 65th American Society of
Hematology (ASH) Annual Meeting and Exposition being held at the
San Diego Convention Center in
San Diego and virtually on
December 9-12, 2023.
Details for the Company's cell therapy presentations are as
follows:
Title: Early Safety Results of P-BCMA-ALLO1, a Fully
Allogeneic Chimeric Antigen Receptor T-Cell (CAR-T), in Patients
with Relapsed / Refractory Multiple Myeloma (RRMM)
Session Title and Location: 704. Cellular
Immunotherapies: Early Phase and Investigational Therapies: Poster
II; Halls G-H
Session Date/ Time: Sunday, December
10, 2023, at 6:00 – 8:00 PM
PT
Publication Number: 3479
Title: A Tumor-Bearing Murine Xenograft Model as
a Bioassay for Assessing CAR-T Product Potency Shows Positive
Predictive Value for Clinical Performance
Session Title
and Location: 803. Emerging Tools, Techniques and
Artificial Intelligence in Hematology: Poster; Halls G-H
Session Date/ Time: Saturday,
December 9, 2023, at 5:30 – 7:30 PM
PT
Publication Number: 2293
Details for the Company's gene therapy presentation are as
follows:
Title: Effective Gene Therapy for Hemophilia A: Novel
Re-Dosable Non-Viral Formulation That Provides Stable, and Durable
FVIII Expression with Improved Tolerability
Session Title
and Location: 321. Coagulation and Fibrinolysis: Basic and
Translational: Poster I; Halls G-H
Presentation Date/ Time: Saturday,
December 9, 2023, at 5:30 – 7:30 PM
PT
Publication Number: 1232
A fourth abstract on the editing efficiency of the in vivo
Cas-CLOVER™ Site-Specific Gene Editing System and off-target
activity in human hepatocytes has been selected for publication in
the November supplemental issue of the ASH journal
Blood.
All abstracts are available on the ASH website at
www.hematology.org.
About P-BCMA-ALLO1
P-BCMA-ALLO1 is an allogeneic CAR-T product candidate licensed
to Roche targeting B-cell maturation antigen (BCMA) for the
treatment of relapsed/refractory multiple myeloma in Phase 1
development. This allogeneic program includes a VH-based binder
that targets BCMA and has shown early evidence of encouraging
safety and efficacy. Additional information about the Phase 1 study
is available at www.clinicaltrials.gov using identifier:
NCT04960579.
About P-FVIII-101
P-FVIII-101 is a liver-directed gene therapy partnered combining
Poseida's piggyBac platform and nanoparticle delivery technologies
for the in vivo treatment of Hemophilia A. Hemophilia A is a
bleeding disorder caused by a deficiency in Factor VIII production
with a high unmet need. P-FVIII-101 utilizes the piggyBac gene
integration system delivered via lipid nanoparticle, which has
demonstrated stable and sustained Factor VIII expression in animal
models.
About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biopharmaceutical
company advancing differentiated cell and gene therapies with the
capacity to cure certain cancers and rare diseases. The Company's
pipeline includes allogeneic CAR-T cell therapy product candidates
for both solid and liquid tumors as well as in vivo gene therapy
product candidates that address patient populations with high unmet
medical need. The Company's approach to cell and gene therapies is
based on its proprietary genetic editing platforms, including its
non-viral piggyBac® DNA Delivery System, Cas-CLOVER™
Site-Specific Gene Editing System and nanoparticle and hybrid gene
delivery technologies as well as in-house GMP cell therapy
manufacturing. The Company has formed a global strategic
collaboration with Roche to unlock the promise of cell therapies
for patients with hematological malignancies. Learn more at
www.poseida.com and connect with us on X and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-to-present-at-the-65th-ash-annual-meeting-and-exposition-301974989.html
SOURCE Poseida Therapeutics, Inc.
